Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 6, 2009, Pages 564-569

  Choi, Jong Won ^a,b   Park, Jun Yong ^a,b   Ahn, Sang Hoon ^a,b   Yoon, Ki Tae ^a,b   Ko, Heung Kyu ^a   Lee, Do Yun ^a   Lee, Jong Tae ^a   Kim, Kyung Sik ^a   Choi, Jin Sub ^a   Han, Kwang Hyub ^a,b   Chon, Chae Yoon ^a,b   Kim, Do Young ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

Hepatocellular carcinoma; Recurrence; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; GELATIN SPONGE; IODINATED POPPYSEED OIL; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CHEMOEMBOLIZATION; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RECURRENT CANCER; TUMOR VOLUME; CANCER STAGING; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 73349099035     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181967da0     Document Type: Article

References (35)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-285.
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(suppl 2):S72-S78.
3. Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg. 1998;85:1319-1331.
4. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942-1956.
5. Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol. 2003;39(suppl 1):S59-S63.
6. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397- 406; discussion 397-406.
7. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003;138:1198 -1206; discussion 1206.
8. Cha C, Fong Y, Jarnagin WR, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197:753-758. (Pubitemid 38199576)
9. Shah SA, Greig PD, Gallinger S, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006;202:275-283.
10. Chen WT, Chau GY, Lui WY, et al. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol. 2004;30:414-420.
11. Poon RT, Fan ST, O'Suilleabhain CB, et al. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg. 2002;195:311-318.
12. Hu RH, Lee PH, Yu SC, et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery. 1996;120:23-29.
13. Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227: 80-85.
14. Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216-222.
15. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703-710.
16. Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology. 2001;34:707-713.
17. Taura K, Ikai I, Hatano E, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265-273.
18. Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol. 2007;14:2319-2329. (Pubitemid 47174899)
19. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461-469.
20. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
21. Yamasaki S, Makuuchi M, Kosuga T, et al. Staging system of hepatocellular carcinoma in general rule for liver cancer. 4th version and TNM classification [Japanese] . Kan Tan Sui. 2000;41:473-480.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
23. Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114-117.
24. Chen MF, Hwang TL, Jeng LB, et al. Postoperative recurrence of hepatocellular carcinoma. Two-hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg. 1994;129:738-742.
25. Tralhao JG, Dagher I, Lino T, et al. Treatment of tumor recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients. Eur J Surg Oncol. 2007;33:746-751.
26. Shimamura T, Une Y, Nakajima Y, et al. [Efficacy of transarterial embolization combined with percutaneous ethanol injection therapy for recurrent hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1994;21:2229-2232.
27. Su YC, Chen LT, Jan CM, et al. Reappraisal of gastroduodenal lesions after transcatheter arterial chemoembolization of liver neoplasms-selective versus superselective method. J Clin Gastroenterol. 1994;18:118-121.
28. Kuroda C, Iwasaki M, Tanaka T, et al. Gallbladder infarction following hepatic transcatheter arterial embolization. Angiographic study. Radiology. 1983;149:85-89.
29. Makuuchi M, Sukigara M, Mori T, et al. Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology. 1985;156:331-334.
30. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(suppl 1):S179-S188.
31. Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery. 2007;141:589-597.
32. Liem MS, Poon RT, Lo CM, et al. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol. 2005;11:4465-4471.
33. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
34. Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14:2337-2347.
35. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-235.